CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. - Wikidata - awgldk - TriplyDB

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

http://www.wikidata.org/entity/Q34677193

about

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer Tamoxifen and CYP2D6: a contradiction of data.Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients Adjuvant Systemic Therapy of Breast Cancer.Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review.Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.The role of genetic breast cancer susceptibility variants as prognostic factors.Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.Clinically relevant drug interactions in anxiety disorders.The importance of nonpharmacogenetic factors in endocrine therapy.CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?The Underrated Risks of Tamoxifen Drug Interactions.Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark

P2860

Q34065337-6AEEC19F-ECDB-4437-A203-0ABCF7E64A40 Q34244463-0104E173-5D59-4BE5-A66A-A6AFB1355C2E Q34736986-82F20854-E0E4-4A95-809D-92CF3BD583B4 Q34768999-1D27D9F3-23B9-405F-9421-BD8FCE8B9AD6 Q35009604-C3774FC9-4E0B-410C-8D74-A3F16D954376 Q35056229-C7462BCE-6570-4E3A-98A2-CD042497E5F0 Q35058455-7407626F-B820-46D2-A499-99ED86EF23F8 Q35092002-02716141-E741-4647-BF20-19622675FEE1 Q35095595-9BF2630A-79D7-4921-B37A-5F0CE2B5F7C7 Q35143365-C1C7B751-C478-4B1E-99B4-0E3F8699B8F5 Q35204531-96B3D56B-1A9B-4556-9008-8FB2A8E447DF Q35690804-021F91D3-5385-4EAE-8875-54A9944B0E9C Q35747766-AA384B8F-9266-4C22-B245-87CAC2A7ED4B Q35842986-5E6BE2C1-6A2B-41D8-9E8F-F3E0C59D83C5 Q35884159-8EB2572B-B1A1-4DEF-A9AD-A777142B2163 Q36142060-C7B84AA9-D0F3-48C6-905D-434497F73BF4 Q36310554-88759AB7-5A7E-4D52-B456-D7F69C962729 Q36535678-5458DE14-CE4C-4158-B797-7F4D68BB3733 Q36545056-8BA5C1FB-3079-4F5C-A4B8-BF10482DB357 Q36727678-A2245772-79E6-45EF-A3A6-B4E2074E6262 Q36729040-14F51569-A6CF-4B6D-ADC1-67508CFE7A25 Q37091709-326FF0C2-3D9C-4F41-855F-9EECC8A0B89D Q37234841-ADB28399-DBC0-4434-96B5-E5CCF1B919C4 Q37464084-B828328D-6313-4CED-A87C-082713D363AF Q37981951-44A1C489-7EB2-4CC4-9634-034F37F4C2A2 Q38003706-1123BDFA-532C-4335-90C4-B6770F87A2DF Q38109822-32DB03D0-0C05-4FC1-8303-4203F8008C1E Q38364888-7A815CCB-6B51-4AE7-A357-556B1955D63D Q39042324-E5240D84-8B4A-4252-A175-9307C25E1998 Q40148639-5FB46736-3272-42E0-8FA4-28BBFDFF3528 Q43987491-0147EACE-AF79-4CDA-AC19-BCE26C95CFBE Q46928874-3F7480C3-A94A-4A01-AA77-19DFB795F319 Q47372688-5CDF3808-800D-4EF5-B7ED-1421F3030766 Q50709557-B2FE5335-1D75-4280-BD0F-7AAE7ED38F4D Q52325476-F70E17F3-D1EA-4985-A160-B546F78F01B8 Q57108405-EC532F57-C63B-40B1-9C25-CBB48C4B6DE6

P2860

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

http://www.wikidata.org/entity/Q34677193

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@ast

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@en

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@nl

type

label

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@ast

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@en

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@nl

prefLabel

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@ast

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@en

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@nl

P1433

Q34677193-C165FC0C-388D-47D8-A2D8-E1B712A10500

P1476

Q34677193-F700B3D9-781A-4478-9B0F-8ABD4F8604F8

P2093

Q34677193-165C00D7-3B31-4614-8086-0E8431524C32

Q34677193-450150D2-389A-4058-96AE-35EDB45BB110

Q34677193-498AEB95-0C2B-4E59-903A-5C1052E2C7A6

Q34677193-7B0A8C52-B7FA-4C5A-A876-F0D02C863B75

Q34677193-A5E7099D-926B-4763-B0B0-A11B22F57228

Q34677193-D2261490-ACD9-496B-BD76-3F5788939ED2

Q34677193-D5A013EE-C787-4E79-AEF4-5F036E48B80E

P2860

Q34677193-00F030E7-EC7D-4325-9C06-CE5AB20C1092

Q34677193-01FA865A-E04C-49A9-8C2A-6AB13E05C245

Q34677193-0E0EAB4C-B4F7-4A21-A6CA-EBBE4781E37F

Q34677193-0F73FE28-505C-47B1-875B-F27652EF3B79

Q34677193-179AD664-C078-4345-A06E-41BCC0501873

Q34677193-199BA75F-F045-492F-98BE-6D85073C55E0

Q34677193-1A155EDA-C76B-4A70-9E1B-F7A8ED1848BB

Q34677193-20AD45D4-E2AE-4ECB-8AE3-52C6F5100419

Q34677193-238679B5-608D-4241-B60B-736B9240181B

Q34677193-245970B1-3B7E-4961-B220-172102D8FC5F

P304

Q34677193-6A967C1F-DB91-4EE2-9E66-CD15DDBE8A3C

P31

Q34677193-907D218F-13BF-4627-9271-DA4937264AFA

P356

Q34677193-CAEB99AD-45FC-4AC9-B1F5-AD82DF94EF60

P407

Q34677193-1903096E-21B0-4E55-AF69-D441DE5A5B7E

P433

Q34677193-39B54B3A-FEA2-4C9F-B16F-6E1B00F53A4A

P478

Q34677193-AEBCC5FF-A460-44B5-9649-9B4D10404F4A

P50

Q34677193-3633C2C1-6659-443D-A3B4-34CA561D62C8

Q34677193-59750ECD-DE78-4E1A-8578-3CE6202D2540

Q34677193-68EA5D1C-715B-467B-8C85-21325030383B

Q34677193-B55D8BB2-49BF-4DC1-AC72-84DA552C8A38

Q34677193-DC7557D7-91B5-4AC9-B594-50076989B6A7

Q34677193-F271700B-4D94-4E0D-BBF8-B50AFF255540

P577

Q34677193-B1AD850A-1540-44CB-BBDF-7E7DAC583CAE

P5875

Q34677193-856328C2-2CD4-4FCA-B2EF-A1E7DC9345A2

P698

Q34677193-6AAE7FE7-880E-43BA-B2E9-A2132BD06352

P932

Q34677193-48717CC8-EAA9-443E-8203-0DE0E53B02FD

P356

P1433

Journal of the National Cancer Institute

P1476

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

@en

P2093

Carol L Rosenberg

http://www.w3.org/2001/XMLSchema#string

Deirdre Cronin-Fenton

http://www.w3.org/2001/XMLSchema#string

Jens Peter Garne

http://www.w3.org/2001/XMLSchema#string

Lars Pedersen

http://www.w3.org/2001/XMLSchema#string

Mariann Christensen

http://www.w3.org/2001/XMLSchema#string

Timothy L Lash

http://www.w3.org/2001/XMLSchema#string

Ylva Hellberg

http://www.w3.org/2001/XMLSchema#string

P2860

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

A comprehensive review of genetic association studies

Evaluation of the potential excess of statistically significant findings in published genetic association studies: application to Alzheimer's disease

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Fallibility in estimating direct effects

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Pathways to tamoxifen resistance.

Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study.

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

P304

489-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR010

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Kathryn L. Lunetta

Stephen Hamilton-Dutoit

Rebecca A Silliman

Henrik Toft Sørensen

Deirdre Cronin-Fenton

P577

2011-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49839809

http://www.w3.org/2001/XMLSchema#string

P698

21325141

http://www.w3.org/2001/XMLSchema#string

P932

3057982

http://www.w3.org/2001/XMLSchema#string